About Us
RAINs medical research and development is focused on serving the world with our innovative technology to fight against antimicrobial resistance or SUPERBUGS, widely recognized as the largest threat to global health. Why RAIN? Rain is a blessing to the earth as it brings life to all that it touches and this is exactly what our technology will do as we are completing our pre-clinical validation and preparation for our regulatory pathway to bring GENESYS to the GLOBAL market.
What we do...
RAIN Scientific is a biomedical engineering company focused on our platform technology that we call GENESYS. GENESYS is a unique combination device medical device with a drug primary mechanism of action. Our initial focus is to support the fight against SEPSIS and antimicrobial resistance...
Who we are...
A passionate and diverse group of professionals from both the medical and industrial sectors that have come together to launch our amazing technology, which once available, will make a significant impact on global health supporting the fight against the worst resistant bacterial strains.
Who Is RAIN Scientific?
Research...
Rain Scientific Inc. is currently collaborating with leading research institutes and is focused on the fight against multi-drug resistant organisms (MDROs) GENESYS delivers a new classification of drug directly into the venous system at the physiological optimum for the pathogen being treated. MDROs are widely accepted as the largest threat to global health so we couldn't be more excited about the market we will serve.
Updates...
October 2021: RAIN has completed in vitro research which has shown solid efficacy against AMR pathogens. RAIN has also successfully completed early safety trials leading to our upcoming GCP Human Safety trials.
December 2022: RAINs regulatory team has completed their regulatory review of our technology, its best possible application, which has led to a clearly defined regulatory path forward.
Fall 2023: RAIN continues to work with our research collaborators and have nearly completed our advanced ex vivo and hollow fiber testing, which will followed with animal in vivo trails scheduled to begin Q1 - 2024.
Q1- 2024: GENESYS is now at design freeze and in the final pre-clinical phase of development. Also, animal testing is scheduled and should be completed by the end of Q3 -2024 - STAY TUNED!!!
We are excited about the where we are at and look forward to sharing more here as things continue to develop...
Meet the TEAM
Tim Koehler - Board Member, CEO, Founder
Rodney Chan, MD - Chief Scientific Officer
Tim Koehler - Board Member, CEO, Founder
A global entrepreneur with 40 years of executive and international business experience. Successful across multiple industries using his engineering education, team approach to every aspect of each venture, manufacturing expertise, and persistence and creativity from start-up to exit.
Mike Davis, MD - Chief Medical Officer
Rodney Chan, MD - Chief Scientific Officer
Tim Koehler - Board Member, CEO, Founder
Board certified plastic surgeon, US Dept. of Defense 25 years, retired COL, held positions as Deputy Commander of Institute of Surgical Research and Director of Combat Casualty Care Research Program
Rodney Chan, MD - Chief Scientific Officer
Rodney Chan, MD - Chief Scientific Officer
Rodney Chan, MD - Chief Scientific Officer
Board certified plastic surgeon, top burn surgeon in history of US Dept. of Defense, founder METIS foundation. MIT – Harvard medical educated.
JEFF ANTOLIK, CHIEF OPERATING OFFICER
Bryan Chuprinko, PMP IND Project Manager
Rodney Chan, MD - Chief Scientific Officer
35 years healthcare industry. Retired VP of Clinical Operations of UnitedHealthcare with extensive experience in operations, process efficiencies, business strategy, culture leadership, provider contracting and reimbursement
Bryan Chuprinko, PMP IND Project Manager
Bryan Chuprinko, PMP IND Project Manager
Bryan Chuprinko, PMP IND Project Manager
Successful and accomplished project manager in life sciences, managing projects from $20K to $18M. Strong communication and collaboration skills drives his projects with less delays and under budget.
Chris Salamone - Outside Legal Counsel
Bryan Chuprinko, PMP IND Project Manager
Bryan Chuprinko, PMP IND Project Manager
Successful corporate attorney and litigator, NY Times best selling author, started and successfully exited three companies. Strong experience in capital, legal and strategic business decisions.
Rich Macary - Strategic Business Advisor
Bill Glauser, PhD Chemistry, Pharma Advisor
Bill Glauser, PhD Chemistry, Pharma Advisor
Ex Wall Street executive now consultant to biotech companies which has led to multiple exits. Strong expertise in capital raise, corporate strategy, regulatory and collaboration with DOD and Gov’t agencies
Bill Glauser, PhD Chemistry, Pharma Advisor
Bill Glauser, PhD Chemistry, Pharma Advisor
Bill Glauser, PhD Chemistry, Pharma Advisor
Computational Chemist, accomplished medical executive in drug and small molecule discovery, regulatory and business development. Innovator in Voice of Customer studies to sharpen company value propositions.
David Helmer - Board Member, Device Advisor
Bill Glauser, PhD Chemistry, Pharma Advisor
John Allen - Board Member, Investment Advisor
35 years international medical device experience. Founded Helmer Scientific, exited 2023. Partner and Founder of multiple founding platforms for early-stage life science and technology start-ups. Passionate global entrepreneur and investor
John Allen - Board Member, Investment Advisor
Paul Frankhouser - Board Member IP Advisor
John Allen - Board Member, Investment Advisor
Founder Coddle Creek Capital, VC in Kannapolis, NC. Engaged consultant to privately held, early-stage companies assisting with market strategy, capital raising and more in life sciences and technology.
Paul Frankhouser - Board Member IP Advisor
Paul Frankhouser - Board Member IP Advisor
Paul Frankhouser - Board Member IP Advisor
Retired VP of Business Development and R&D for worlds largest catheter manufacturer. Literally was responsible for every product brought to market ending in $2B exit in 2005. Engineer and an Expert in IP, go-to-market and product development
Phillip F. Burris -Inventor, Co-Founder, Technical Advisor
Paul Frankhouser - Board Member IP Advisor
Paul Frankhouser - Board Member IP Advisor
Masters in Electrical Engineering, UC Berkley. 25 years at Lawrence Livermore National Laboratory. Inspired to invent original device when his favorite Uncle Joe came down with debilitating disease. After full recovery, failed to gain traction and project died. Met Tim Koehler in 2016, assigned technology over to what has become RAIN Scientific today.